PubMed Health⌕ Search

Biomedical subjects

M Tudino

Publications and source records attributed to M Tudino.

2 recordsLinked to original sources

Oscillatory control of sample dispersion in a continuous flow system.

A new strategy for the instrumental control of sample dispersion in continuous flow systems is presented. The method is based on shaking a loosely held straight reactor while the sample travels through the flow injection manifold. This external disturbance yields a sample transport more similar to the plug flow type because of the changes promoted on the flow pattern. Up to a three-fold increase in peak height, a comparable reduction in peak width and a more Gaussian peak profile are observed when the signals obtained with the shaken reactor are compared with those obtained with the same reactor but static. Improvements in the analytical performance as a function of different operational variables are shown for systems with or without a chemical reaction. Analytical implications and possible uses are discussed since this strategy allows the control of dispersion by simply selecting the frequency and amplitude of oscillation.

Journal Article↗

Oral aluminum administration to rats with normal renal function. 2. Body distribution.

Aluminum (Al) has no known physiological function and is not considered an essential dietary compound. Nowadays, it is recognized as an element that can produce adverse effects on biological systems. The present study determined Al partitioning in the body compartments of rats that have been orally exposed for 15 weeks. Three experimental groups were studied: Controls (C, n=19), TAl-1 (n=10) rats receiving daily doses of Al citrate (1.0 micromol/g body weight) by gavage and TAl-2 (n=13), receiving Al citrate with the drinking water (100 mmol/ l). At the end of the experimental period, the Al contents of organs and sera were determined. Results are expressed as median and range values. Comparing the TAl-2 rats with the control ones, remarkable Al accumulation could be observed in serum (4.8/2.7-16.3 vs 0.4/0.2-1.2 micromol/l, P<0.001), bone (3.33/1.78-4.85 vs 1.00/0.48-1.59 micromol/ g, P<0.001), kidney (2.33/0.96-3.15 vs 0.52/0.22-2.07 micromol/g, P<0.001), spleen (2.22/0.70-4.19 vs 0.27/ 0.11 - 0.36 micromol/g, P< 0.001) and liver (0.60/0.42-0.91 vs 0.24/0.14-0.78 micromol/g, P<0.01) while brain Al content was not significantly increased. Aluminum levels were raised in the TAl-1 group only in serum (2.8/1.3 - 10.4 micromol/ g, P < 0.001), bone (1.85/1.00-3.41 micromol/g, P < 0.001) and kidney (1.74/0.96-2.07 micromol/g, P<0.01). Bone Al concentration increased in a dose-dependent manner (TAl-2 vs TAl-1, P<0.001). The results demonstrate different tissue Al accumulation in rats chronically exposed to Al citrate, irrespective of their intact renal function.

Administration, Oral↗